Disease Overview：Hemolytic Uremic Syndrome（HUS）
Hemolytic Uremic Syndrome (HUS) is a rare, life-threatening thrombotic microangiopathy characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. It most commonly arises from Shiga toxin–producing Escherichia coli (STEC) infection—particularly O157:H7—but may also occur atypically due to complement dysregulation (e.g., mutations in CFH, CFI, or MCP), autoimmune disorders, or drug exposure. Renal involvement ranges from mild proteinuria to rapidly progressive glomerular injury with cortical necrosis; approximately 5–10% of pediatric STEC-HUS cases progress to end-stage kidney disease, while atypical HUS carries higher recurrence and chronicity risks. Diagnosis relies on peripheral blood smear (schistocytes), lactate dehydrogenase elevation, haptoglobin depletion, low platelets, and renal function assessment—including urine microscopy, serum complement profiling, and genetic testing when indicated. Management involves supportive care (fluid/electrolyte balance, transfusion if indicated), plasma exchange for atypical HUS, and targeted complement inhibition (eculizumab/ravulizumab) in refractory or genetically confirmed cases.
China offers distinct advantages in HUS management: leading nephrology centers—such as Peking University First Hospital and Shanghai Renji Hospital—maintain dedicated thrombotic microangiopathy programs with multidisciplinary expertise in complement genetics, plasmapheresis optimization, and precision immunomodulation. Advanced diagnostics include next-generation sequencing for complement pathway variants and real-time monitoring of soluble C5b-9. Clinical outcomes align with international benchmarks: over 85% of pediatric STEC-HUS patients achieve full renal recovery, and eculizumab-treated atypical HUS cohorts demonstrate >90% 1-year renal survival. Treatment costs are typically 40–60% lower than in the US or Western Europe, without compromising protocol adherence or monitoring rigor. As a medical tourism agency, we facilitate seamless access to these high-volume, evidence-based programs—handling hospital referrals, coordinating pre-arrival diagnostic reviews, ensuring transparent all-inclusive pricing, and providing end-to-end support including visa assistance, interpreter services, and post-discharge follow-up coordination.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Hemolytic Uremic Syndrome (HUS) — Nephrology Department
Non-Surgical / Conservative / Medication Management
*Indicated for atypical HUS (aHUS) with complement dysregulation, mild-moderate renal impairment (eGFR ≥30 mL/min/1.73m²), and absence of life-threatening microangiopathic hemolysis or neurological involvement.*
- •Eculizumab (anti-C5 monoclonal antibody):
- *Cost per dose*: $2,850–$3,100 (Grade 3A hospital pharmacy pricing; 30 mg/mL vial × 30 vials/course)
- •Ravulizumab (longer half-life anti-C5):
- *Cost per infusion*: $5,200–$5,600
- •Supportive Care (per 7-day admission):
- Erythropoietin + iron supplementation: $120–$180 - Renal function monitoring (creatinine, LDH, haptoglobin, platelet count, peripheral smear): $210–$260 - Daily electrolyte panel + coagulation profile: $140–$170
Surgical / Procedural / Interventional Options
*Eligibility: Refractory aHUS with eGFR <15 mL/min/1.73m², dialysis dependence, or thrombotic microangiopathy unresponsive to complement inhibition after ≥4 weeks.*
- •Therapeutic Plasma Exchange (TPE):
- *Procedure cost (single session, 1.5 plasma volumes)*: $480–$550 (includes albumin replacement, circuit anticoagulation, nursing time) - *Typical course*: 10–14 sessions over 2–3 weeks → $4,800–$7,700 total
- •Kidney Biopsy (for diagnostic confirmation in ambiguous cases):
- *Ultrasound-guided native kidney biopsy (12-gauge needle, ≥3 glomeruli)*: $1,150–$1,320 - *Light/electron microscopy + immunofluorescence*: $890–$1,030
Special / Complex Condition Management
- •HUS with STEC infection (typical HUS): Supportive care only; antibiotics contraindicated. Dialysis required in 50% of pediatric cases:
- *Peritoneal dialysis catheter placement + 30-day PD training*: $2,100–$2,450
- •Post-transplant aHUS recurrence:
- *Living-donor transplant (surgery + 30-day immunosuppression)*: $22,500–$26,800
Quick Selection Guide
- •Children (<12 years) with STEC-HUS: Start supportive care + dialysis if needed ($320–$380/session); avoid complement inhibitors unless genetic aHUS confirmed.
- •Adults with confirmed *CFH/CFI* mutation & eGFR <30: Initiate ravulizumab ($5,200–$5,600/dose) — superior cost-efficiency vs. weekly eculizumab over 1 year.
- •Budget-constrained patients (out-of-pocket >¥50,000): TPE monotherapy ($4,800–$7,700 course) remains first-line where eculizumab unavailable.
- •Severe neurologic involvement or multiorgan failure: Urgent TPE + ICU admission ($1,400–$1,700/day) + immediate complement inhibitor initiation.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Hemolytic Uremic Syndrome Medical Vacation Packages
Curated transparent all-inclusive packages combining Hemolytic Uremic Syndrome treatment with China top medical destinations:
